SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: mulanoon2007 who wrote (3981)11/10/2015 8:57:25 PM
From: jaybe  Respond to of 4474
 
FGFR1 is essential, doubtful either of those will have meaningful activity in FGFR1 NSCLC, pona is 30-60 fold more potent. See below.

IC50 (nM) FGFR1/ VEGFR2/ PDGFRa
pazopanib 140/ 8/ 30
nindetanib 69/ 21/ 59
ponatinib 2.2/ 1.2/ 1.1